The earnings transcript for Merck & Co., Inc. indicates several positive factors that are likely to influence the stock price in the short term:

1. **Strong Growth in Key Products**: Merck reported strong growth driven by KEYTRUDA, GARDASIL, and other oncology and vaccine products. KEYTRUDA's global sales nearly doubled year-over-year, and GARDASIL saw significant growth, especially with its recent approval in China[3].
2. **Robust Financial Performance**: Total company revenues increased by 5% year-over-year, and the company narrowed and raised its EPS guidance range for 2018 despite less favorable exchange rates[3].
3. **Positive Regulatory Milestones**: Merck achieved several important regulatory milestones, including multiple approvals and filings for KEYTRUDA, Lynparza, and LENVIMA, which are expected to drive future growth[3].
4. **Confident Outlook**: Management expressed confidence in the long-term growth prospects, particularly in oncology, vaccines, and animal health. The company is investing heavily in R&D to support future growth, which indicates a strong strategic direction[3].

Given these points, the overall tone of the transcript is positive, suggesting that the stock is likely to experience upward pressure in the short term.

**Rating: 2**